



























Link to publication record in King's Research Portal
Citation for published version (APA):
Spicer, J., Chamberlain, C., & Papa, S. (2020). Provision of cancer care during the COVID-19 pandemic. Nature
Reviews Clinical Oncology, 17(6), 329-331. https://doi.org/10.1038/s41571-020-0370-6
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. Jul. 2021
Provision of cancer care during the COVID-19  pandemic 
James Spicer1,2, Charlotte Chamberlain3 and Sophie Papa1,2 
 
1 School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK. 
2 Guy’s & St Thomas’ NHS Foundation Trust, London, UK. 




Health-care services are rapidly transforming their organization and workforce in 
response to the coronavirus disease 2019 (COVID-19) pandemic. These changes, and 
a desire to mitigate infection risk, are having profound effects on other vital aspects 
of care, including the care of patients with cancer. Difficult decisions are being made 
regarding the prioritization of both active treatments and palliative care, despite 
limited evidence that cancer is an independent risk factor for infection and mortality. 
 
COVID-19 outcomes in patients with cancer 
According to published data from China reported by Liang et al.1, cancer seems to have 
comparable associations with an increased risk of death from coronavirus disease 2019 
(COVID-19) to those of other comorbidities, such as chronic respiratory disease and 
hypertension. However, whether the multivariate analysis that suggested this association 
accounted for the potential confounding effects of noncancer comorbidities remains unclear. 
Conclusions thus far have had to be drawn from the analysis of data from small subgroups 
of patients with cancer in much larger population-based series. In a correspondence2, the 
authors highlight that half of the patients with cancer included in the analysis by Liang et al.1 
were diagnosed >4 years before SARS-CoV-2 infection, suggesting that these patients 
might not have active cancer. The observations by Liang et al.1 might, therefore, not be 
generalizable to patients with cancer requiring ongoing treatment and/or management who 
develop COVID-19. In comparison to those without cancer, as expected, the patients with 
cancer included in the study by Liang et al.1 were older (mean age of 63 years versus 49 
years), and this might be a powerful confounder given the strong correlation between 
advanced age and death from COVID-193. In other reports of risk factors in patients with 
COVID-194,5, the authors have not analysed cancer as a comorbidity, presumably owing to 
small sample sizes and the generally low prevalence of cancer at the population level.  
 
In marked contrast to data from China, a preliminary report from Italy indicates that 20% of 
patients with COVID-19 had a diagnosis of cancer in the preceding 5 years6. However, in 
this analysis, the identification of comorbidities was confined to patients who died of COVID-
19; therefore, distinguishing between cancer as an independent risk factor for developing 
COVID-19 or for poor outcomes is not possible. Analysis of incidence and outcomes 
specifically in patients with cancer and COVID-19 will enable a clearer understanding of the 
associated risks. 
 
Acute management and palliative care 
The presenting features of COVID-19, such as fever, fatigue, dyspnoea and 
arthralgia/myalgia, are often similar to those of patients with cancer, especially those 
receiving treatment. Therefore, the recognition of COVID-19 symptoms in such patients can 
be problematic. Guidelines provided by the UK National Institute for Health and Care 
Excellence (NICE) state that if the differential diagnosis includes the possibility of 
neutropenic sepsis, this must first be excluded as this is the most immediately life-
threatening condition7. In the inpatient setting, those without suspected COVID-19 must be 
segregated from those with established or suspected COVID-19. Furthermore, a high 
proportion of hospitalized patients with COVID-19 will require respiratory support. For 
patients with cancer, the appropriate level of escalation of care for COVID-19 symptoms is 
likely to be affected by the patient’s expected survival duration based on disease stage, 
treatment history and 
pre-morbid performance status. Carers need to encourage their patients to discuss in 
advance their priorities for treatment escalation because critical care, including ventilatory 
support, is likely to be explicitly rationed in most health-care systems and is unlikely to be 
successful in many patients with advanced-stage cancer. Reduced availability of community 
symptom support might result in an increase in hospital admissions at a time when many 
health-care systems are least able to manage such increases. Already under-resourced 
palliative care teams are likely to face staffing crises just when demand increases 
exponentially. These issues have implications for patients with cancer and their families 
affected by COVID-19, as well as for those with life-limiting cancer without COVID-19, 
whose symptoms might deteriorate as a result of reduced health-care provision. 
 
COVID-19 also presents a barrier to hospice admission and, therefore, oncologists are likely 
to be required to manage certain complex symptoms that would otherwise benefit from the 
involvement of palliative care teams. Guidance on the adaptation of palliative care to the 
demands of the COVID-19 pandemic has been provided by the Center to Advance Palliative 
Care, and the European Association for Palliative Care have provided advice for non-
specialists on counselling patients who have become critically unwell owing to COVID-19.  
 
Practical end-of-life care considerations in the context of the COVID-19 pandemic include 
limitations of visitor access to patients, even for close relatives, owing to concerns regarding 
viral transmission. These considerations might be compounded by restricted supplies of 
personal protective equipment in certain health-care systems and restricted mortuary and 
funeral arrangements enforced by capacity constraints and/or public health measures. Thus, 
the negative psychological sequelae of the pandemic, which could lead to suboptimal care, 
symptom management and end-of-life care, might be substantial for patients with cancer, 
their families and/or their carers. 
 
Service reconfiguration during the pandemic 
Social distancing, lockdowns and curfews are creating major long-term issues for both 
curative and palliative oncology care. Patients need to be managed, as far as possible, 
without visits to hospitals or other treatment centres in order to minimize infection risk and by 
applying the precautionary principle as more data on infection risks are gathered8. This 
aspect, in addition to the re-deployment of resources to acute COVID-19 care, creates 
problems with the delivery of timely treatment, the continuity of care and access to clinical 
trials, most of which are now closed to recruitment. Patients with fever or respiratory 
symptoms need to be triaged on arrival at the cancer centre in order to reduce the risk of 
exposure to other patients and staff. Access to SARS-CoV-2 testing for patients can help 
with this triage. Testing of staff, a problem even in the health-care systems of many 
economically developed countries, defines a return-to-work pathway that is essential for 
maintenance of a stable workforce.  
 
Remote review by telephone or video-link can be used in routine outpatient practice, when 
the benefits of attending hospital in person are judged to be outweighed by the risks of 
exposure to infection7. Other methods of reducing the need for patients to travel include 
home deliveries of oral medicines, local and/or remote availability of routine clinical testing, 
and remote consenting and rationalization of investigations. Increased operating hours of 
outpatient services and the provision of cancer-specific acute evaluation capabilities can all 
help in relieving the pressures placed on emergency departments. Blood product shortages 
arising from societal effects on donations are likely and can be mitigated in part by raising 
the thresholds for transfusion and through greater use of erythropoietin. Oncology inpatient 
activity is also likely to be fundamentally and rapidly affected, both owing to the necessity of 
reallocating dedicated beds for general respiratory support and as a result of a proportion of 
the outpatient population requiring admission with the co-diagnoses of cancer and COVID-
19. 
 
Effects on infrastructure and staffing levels in cancer services affected by COVID-19 have 
led to some of the most difficult decisions. As highlighted in the UK National Health Service 
(NHS) guidelines in this area, constraints on access to operating theatres and anaesthetic 
support might be a particular problem for patients requiring surgery or brachytherapy9. 
Prioritization of treatment for patients with cancer should, therefore, be formalized to ensure 
that those with the most important implications for oncological outcomes are preferentially 
delivered when resources become constrained7,9. Prioritization of treatment implies rationing 
of care, and these decisions should, where possible, be taken as a team and be discussed 
fully with the patient. When treatment plans deviate from standard practice, this should be 
carefully documented. Prioritization must also take into account and balance the relative 
benefits of treatment against the estimated increased risks of infection. Although we 
recognize the substantial risks of viral infection to all members of the population, COVID-19 
will not harm every patient with cancer. 
 
Treatment delays, the introduction of regimens requiring less-frequent administration and 
hypofractionated radiotherapy are all important components of a pandemic mitigation 
strategy for patients who nonetheless require treatment for other conditions. Delays in the 
delivery of palliative interventions, which are at risk of low-level prioritization in this context, 
might lead to worsening symptoms, a loss of any possible treatment opportunities and 
hospital admission for symptom control at a time when inpatient resources are least 
available. For most patients with solid tumours, the survival benefits obtained with adjuvant 
treatments must be offset against the risks posed by regular clinic attendance for 
myelosuppressive therapy: addition of growth factor support in this setting is now widely 
advocated7. Prioritization of surgical interventions is also important, as is the consideration 
of radical alternatives to surgery, especially radiotherapy, and safe methods of delaying the 
need for surgery such as in women with certain types of breast cancer using endocrine 
therapy, or in men with prostate cancer using androgen-deprivation therapy. Further data 
are required in order to understand how best to extrapolate the current limited understanding 
of the immunology of SARS-CoV-2 to the effects of anticancer immunotherapy. A systematic 
review revealed little evidence that immuno-modulatory agents, such as steroids, cytotoxic 
agents, tacrolimus, JAK inhibitors and biologics, including anti-TNF antibodies, increase the 
risk of severe COVID-19 symptoms10. The use of anti-PD-1 antibodies might, theoretically, 
limit the extent of T cell exhaustion and thus promote viral elimination, or could potentially 
contribute to the excessive inflammatory response to viral infection. 
 
Conclusions 
Data emerging from countries affected early in the COVID-19 pandemic have, thus far, 
provided little evidence to improve our understanding of the effects of having cancer on the 
risk of either SARS-CoV-2 infection or on the outcomes of COVID-19. Prospective collection 
of data on the outcomes of patients with cancer and COVID-19 across all age ranges, 
tumour types and treatment modalities will enable more robust conclusions to be drawn. 
These data need to be rapidly collated and shared. Reassessment of the relative risks and 
benefits of cancer therapies in the context of the COVID-19 pandemic is fundamental to the 
continued safe delivery of these treatments. At the same time, the redeployment of 
infrastructure and personnel across a health-care system might in itself also contribute to 
inferior cancer outcomes. Every effort should be made to avoid compromising the delivery of 
evidence-based cancer care when infection risks are outweighed by the benefits of 
treatment. 
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